Immunodeficiency Virus (e.g., Hiv, Etc.) Patents (Class 424/208.1)
-
Patent number: 8932603Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.Type: GrantFiled: February 25, 2004Date of Patent: January 13, 2015Assignee: Vaccibody ASInventors: Bjarne Bogen, Agnete Fredriksen Brunsvik, Inger Sandlie
-
Publication number: 20150010594Abstract: A method for inducing an immune response against HIV in a subject includes preparing first and second HIV-1 protein coding sequences, introducing the first and second HIV-1 protein coding sequence into first and second expression constructs using yeast homologous recombination, transfecting a cell with the first and second, wherein the HIV-1 particle is secreted by the cell, and administering the secreted HIV-1 particle and a pharmaceutically acceptable carrier to the subject, wherein the secreted HIV-1 particle stimulates an immune response.Type: ApplicationFiled: July 2, 2014Publication date: January 8, 2015Inventor: Yong Gao
-
Patent number: 8926995Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV-1) and, in particular, to a method of enhancing an immune response to an HIV-1 immunogen, and to compounds and compositions suitable for use in such a method.Type: GrantFiled: November 23, 2011Date of Patent: January 6, 2015Assignee: Duke UniversityInventors: Barton F. Haynes, Laurent Verkoczy, M. Anthony Moody, Matt T. Holl, Masayuki Kuraoka, Garnett Kelsoe
-
Publication number: 20150004132Abstract: We have developed DNA and viral vectors that can be used, alone or in combination, as a vaccine against one HIV clade, subtype, or recombinant form of HIV or against multiple HIV clades, subtypes, or recombinant forms. Moreover, the vectors can encode a variety of antigens, which may be obtained from one clade or from two or more different clades, and the antigens selected and/or the manner in which the vectors are formulated (e.g., mixed) can be manipulated to generate a protective immune response against a variety of clades (e.g., the clades to which a patient is most likely to be exposed; with the proportions of the components of the vaccine tailored to the extent of the patient's risk to a particular clade or clades).Type: ApplicationFiled: December 20, 2013Publication date: January 1, 2015Applicants: EMORY UNIVERSITY, Centers for Disease Control and Prevention, The United States of America as Represented by the Department of Health and Human ServicesInventors: Harriet Robinson, James Smith, Ram Amara, Bernard Moss, Salvatore T. Butera, Dennis Ellenberger
-
Publication number: 20140377307Abstract: The present invention provides improved treatment methods by the administration of both an inhibitor of indoleamine-2,3-dioxygenase in addition to the administration of an additional therapeutic agent.Type: ApplicationFiled: October 8, 2013Publication date: December 25, 2014Applicant: GEORGIA REGENTS RESEARCH INSTITUTE, INC.Inventors: DAVID MUNN, ANDREW MELLOR
-
Patent number: 8916174Abstract: The present invention is directed to a DNA vaccine for immunization against HIV. The invention comprises a DNA molecule that has a sequence encoding a plurality of viral proteins capable of stimulating an immune response against HIV. The DNA molecule is rendered safe for use as a vaccine by the disruption of genes encoding reverse transcriptase, integrase, and Vif. The DNA molecule is further rendered safe by at least a partial deletion of the 3? LTR.Type: GrantFiled: July 18, 2011Date of Patent: December 23, 2014Assignees: National Institute for Agricultural Research, University of Kansas Medical CenterInventors: Yahia Chebloune, Euan Narayan
-
Publication number: 20140370052Abstract: The present invention refers to methods and compositions to prevent viral entry into cells expressing the CD169/sialoadhesin surface receptor by inhibiting the coupling of the sialyllactose molecule contained in the viral membrane gangliosides to the CD 169/sialoadhesin receptor. The invention also pertains to vaccine compositions based on dendritic cells loaded with an antigen of interest whereby the vaccine is provided together with a composition capable of preventing viral entry into cells expressing the CD169/sialoadhesin. Moreover, the invention relates to diagnostic and therapeutic compositions that can be specifically delivered to enveloped virions wherein the diagnostic/therapeutic agent is coupled to CD169/sialoadhesin.Type: ApplicationFiled: December 17, 2012Publication date: December 18, 2014Inventors: Nuria Izquierdo Useros, Hans-Georg Krauesslich, Maier Lorizate, Javier Martinez Picado
-
Patent number: 8911728Abstract: The invention provides engineered antibody domains (eAds), a polypeptide comprising a single domain CD4, as well as a fusion protein comprising the same. Nucleic acids encoding eAd and/or polypeptide or the fusion protein thereof, as well as compositions or cells comprising the eAd, polypeptide, fusion protein, or nucleic acid also are provided.Type: GrantFiled: May 20, 2011Date of Patent: December 16, 2014Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Weizao Chen
-
Publication number: 20140341949Abstract: The present invention relates, in general, to an HIV-1 vaccine and, in particular, to a B cell lineage-based vaccination protocol.Type: ApplicationFiled: October 3, 2012Publication date: November 20, 2014Applicants: DUKE UNIVERSITY, Children's Medical Center CorporationInventors: Barton F. Haynes, Garnett Kelsoe, Stephen Harrison, Thomas B. Kepler
-
Publication number: 20140335074Abstract: Methods are provided herein for enhancing the effectiveness of medical therapies by administering agents that suppress a biological damage response that is inducible by the medical therapy administered to a subject. In certain embodiments, a method is provided for administering an anti-senescent cell agent that suppresses a biological response comprising cellular senescence that is induced by the medical therapy.Type: ApplicationFiled: December 13, 2012Publication date: November 13, 2014Inventors: Judith Campisi, Marco Demaria
-
Publication number: 20140335126Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV), and in particular to a vaccine for HIV-1 and to methods of making and using same.Type: ApplicationFiled: December 5, 2012Publication date: November 13, 2014Inventors: Barton F. Haynes, Huaxin Liao, Jerome Kim, Nelson Michael, Susan B. Zolla-Pazner
-
Patent number: 8883745Abstract: The invention is directed to novel synthetic C-glycolipids that selectively induce a ThI-type immune response characterized by enhanced IL-12 secretion and increased activation of dendritic cells. The compounds of the invention are thereby useful in treating infections, cancers, cell proliferative disorders, and autoimmune diseases, both directly and as adjuvants.Type: GrantFiled: May 22, 2007Date of Patent: November 11, 2014Assignees: New York University, The Aaron Diamond Aids Research Center For The City Of New York, Research Foundation Of The City University Of New YorkInventors: Moriya Tsuji, Guangwu Chen, Richard W. Franck, Guangli Yang
-
Publication number: 20140328876Abstract: In one aspect, the present disclosure provides compounds of formulae (I) and (II). In another aspect, a compound of formula (I) or (II) is formulated into compositions with an antigen, optionally with a vesicle. In some embodiments, compositions are administered intramuscularly.Type: ApplicationFiled: November 16, 2012Publication date: November 6, 2014Inventor: Maura Ellen Campbell
-
Publication number: 20140328793Abstract: Compounds, compositions, and methods of treatment and prevention of HIV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient.Type: ApplicationFiled: November 30, 2012Publication date: November 6, 2014Applicant: Emory UniversityInventors: Christina Gavegnano, Raymond F. Schinazi
-
Publication number: 20140322269Abstract: The invention relates to an engineered outer domain (eOD) of HIV gp120 and mutants thereof and methods of making and using the same. The mutant eODs may be advantageous for the elicitation of CD4-binding site (CD4bs)-directed broadly-neutralizing antibodies (bnAbs) and/or improve binding to mature VRC01 and/or improve binding to germline VRC01 and the germlines of other VH1-2 derived broadly-neutralizing antibodies. The mutant eODs may also include glycan-masking mutations on eOD. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity as well as the design of cocktails of different eODs that represent the full diversity of HIV sequences within the VRC01 epitope and surroundings.Type: ApplicationFiled: April 11, 2014Publication date: October 30, 2014Applicants: University of Washington, International AIDS Vaccine Initiative, The Scripps Research InstituteInventors: Po-Ssu Huang, Joseph Graham Jardine, Sergey V. Menis, William Ray Schief, JR., Neil P. King
-
Patent number: 8871219Abstract: Recombinant vectors which are based on the Modified Ankara Virus (MVA) as preventive and therapeutic vaccines against AIDS. The recombinant viruses contain sequences which are inserted at an MVA insertion site and enable simultaneous expression of antigens, a HIV-1 Env protein consisting of a gp120 protein lacking sequences corresponding to protein gp 41 and a chimeric fusion protein of Gag, Pol and Nef. These viruses are stable and can trigger immune responses against a large variety of antigens. Viruses having a chimeric protein from HIV-1 are suitable for the preparation of vaccines against AIDS.Type: GrantFiled: July 25, 2006Date of Patent: October 28, 2014Assignee: Consejo Superior de Investigaciones CientificasInventors: Jonathan Heeney, Petra Mooij, Carmen Elena Gomez Rodriguez, Jose Luis Najera Garcia, Victoria Jimenez Tentor, Mariano Esteban Rodriguez
-
Publication number: 20140314809Abstract: The invention provides a method of identifying an antigen from a pathogen or a disease antigen comprising the use of an adenoviral vector array comprising two or more different adenoviral vectors, wherein each adenoviral vector comprises a nucleic acid sequence encoding a different antigen of a pathogen. The adenoviral vectors are administered to antigen presenting cells (APCs) in vitro or to an animal in vivo. The immunogenicity of the antigen is measured by screening for an immune response from effector T lymphocytes in vitro and by screening for the absence of pathogen-induced disease onset in vivo.Type: ApplicationFiled: April 19, 2013Publication date: October 23, 2014Inventors: Joseph T. Bruder, Imre Kovesdi, Duncan L. McVey, Douglas E. Brough, C. Richter King, Denise Louise Doolan, Joao Carlos Aguair, Daniel John Carucci, Martha Sedegah, Walter R. Weiss, Keith Limbach
-
Publication number: 20140302089Abstract: The present invention relates to pharmaceutical compositions comprising a mixture of a specific HIV antigen and a non-pathogenic living bacterium. Said specific HIV antigen comprises one or more epitopes from Gag and/or Pol proteins and is preferably under a particulate form. Said bacterium is preferably Lactobacillus plantarum. These compositions are useful for preventing and/or treating an HIV disease in humans.Type: ApplicationFiled: April 6, 2012Publication date: October 9, 2014Applicant: BIOVAXIM LIMITEDInventors: Jean-Marie Andrieu, Louis Lu
-
Patent number: 8846051Abstract: Methods of producing a pathogen with reduced replicative fitness are disclosed, as are attenuated pathogens produced using the methods. In particular examples, the method includes deoptimizing one or more codons in a coding sequence, thereby reducing the replicative fitness of the pathogen. Methods of using the attenuated pathogens as immunogenic compositions are also disclosed.Type: GrantFiled: October 7, 2005Date of Patent: September 30, 2014Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Olen M. Kew, Cara C. Burns, Jing Shaw, Raymond Campagnoli, Jacqueline Quay
-
Publication number: 20140248311Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV), and in particular to a vaccine for HIV-1 and to methods of making and using same.Type: ApplicationFiled: July 5, 2012Publication date: September 4, 2014Applicants: DUKE UNIVERSITY, U.S ARMY MEDICAL RESEARCH AND MATERIEL COMMAND, CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Jerome Kim, Stephen Harrison, Barton F. Haynes, Georgia D. Tomaras, Nelson Michael
-
Publication number: 20140234361Abstract: A method for treating an HIV disease in a subject in need of said treatment, comprising administering to the subject a therapeutically effective amount of a DNA vaccine comprising an expression vector and a pharmaceutically acceptable excipient, where the expression vector comprises: (a) a heterologous promoter operatively linked to a DNA sequence encoding a nuclear-anchoring protein, where the nuclear-anchoring protein comprises: (i) a DNA binding domain which binds to a specific DNA binding sequence, and (ii) a functional domain of the Bovine Papilloma Virus Type 1 E2 protein, where the functional domain binds to a nuclear component; (b) a multimerized DNA sequence that forms a binding site for the nuclear anchoring protein; and (c) at least one expression cassette comprising a DNA sequence encoding a protein or peptide that stimulates an immune response specific to the protein or peptide; where the expression vector lacks an origin of replication functional in mammalian cells.Type: ApplicationFiled: January 13, 2014Publication date: August 21, 2014Applicant: FIT Biotech OyInventors: Kai KROHN, Vesna Blazevic, Marja Tähtinen, Mart Ustav, Urve Toots, Andres Männik, Annamari Ranki, Ene Ustav
-
Publication number: 20140227320Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.Type: ApplicationFiled: September 27, 2012Publication date: August 14, 2014Inventors: Shawn P. Iadonato, Kristin Bedard, Myra Wang Imanaka, Kerry W. Fowler
-
Patent number: 8795685Abstract: Described is the use of a mutation of at least one amino acid in the immunosuppressive domain of a HIV or SIV accessory protein, for modulating the immunosuppressive property of the protein.Type: GrantFiled: August 17, 2005Date of Patent: August 5, 2014Assignees: Institut Gustave Roussy, Centre National de la Recherche Scientifique, Universite Paris Sud XIInventors: Martial Renard, Marianne Mangeney, Thierry Heidmann
-
Patent number: 8795682Abstract: Embodiments of the present disclosure encompasses virus-like particles, methods of making virus-like particles, including expression vectors, wherein the virus-like particles may comprise enhanced levels of capsid-bound a chimeric HN-Env polypeptide compared to VLPs derived from unmodified HIV-env polypeptides. Embodiments of the virus-like particle may have Env-specific epitopes exposed on the outer surface thereof. In one embodiment, the Env-specific epitopes exposed on the outer surface of the virus-like particle may specifically bind with an anti-HIV-Env specific antibody. Embodiments of the disclosure further includes methods of generating an antibody specific to an epitope of an HIV-Env polypeptide, comprising delivering to an animal or a human an effective amount of a suspension of virus-like particles comprising a chimeric HIV-Eny polypeptide, thereby inducing the formation of an antibody specific to an epitope of an HIV-1 eny polypeptide.Type: GrantFiled: May 2, 2008Date of Patent: August 5, 2014Assignees: Emory University, The UAB Research Foundation, Novavax, Inc.Inventors: Richard W. Compans, Baozhong Wang, Beatrice Hahn, Weimin Liu, Gale Smith, Peter Pushko
-
Patent number: 8790898Abstract: The present invention relates to chimeric peptides having a caveolin-1 binding domain of an HIV-1 gp41 (CBD1) peptide or a variant of said CBD1, fused to a T helper epitope. In one aspect, the T epitope is from a peptide selected from the group consisting of a tetanus toxin, an HIV-1 Gag p24 and an HIV-1 Env-gp120. Compositions containing these chimeric peptides and pharmaceutical and immunogenic compositions as well as vaccines comprising these chimeric peptides also are part of the present invention. Methods to induce neutralizing antibodies against HIV-1 activity and uses of the chimeric peptides to treat or to prevent HIV-1 infection are also disclosed.Type: GrantFiled: August 27, 2009Date of Patent: July 29, 2014Assignee: Centre National de la Recherche Scientifique (CNRS)Inventors: Ara Hovanessian, Bernard Krust
-
Publication number: 20140205631Abstract: The present invention provides angiotensin peptide compositions and methods for use of the compositions in vaccination.Type: ApplicationFiled: January 21, 2014Publication date: July 24, 2014Inventors: Robert LARSEN, Kathleen E. RODGERS, Gere S. DIZEREGA
-
Publication number: 20140205652Abstract: The present invention relates to, inter alia, a method of raising an immune response against a pathogen which comprises administering (i) one or more first immunogenic polypeptides derived from said pathogen; (ii) one or more adenoviral vectors comprising one or more heterologous polynucleotides encoding one or more second immunogenic polypeptides derived from said pathogen; and (iii) an adjuvant; wherein the one or more first immunogenic polypeptides, the one or more adenoviral vectors and the adjuvant are administered concomitantly. The invention also relates to vaccines, pharmaceutical compositions, kits and uses employing said polypeptides, adenoviral vectors and adjuvants.Type: ApplicationFiled: January 18, 2013Publication date: July 24, 2014Applicant: GlaxoSmithkline Biologicals, s.a.Inventor: Gerald Hermann VOSS
-
Publication number: 20140205612Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.Type: ApplicationFiled: February 28, 2013Publication date: July 24, 2014Applicants: THERACLONE SCIENCES, INC., INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTEInventors: Po-Ying Chan-Hui, Katherine Doores, Michael Huber, Stephen Kaminsky, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Marjorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos
-
Patent number: 8785411Abstract: The present invention is directed to a DNA vaccine for immunization against HIV. The invention comprises a DNA molecule that has a sequence encoding a plurality of viral proteins capable of stimulating an immune response against HIV. The DNA molecule is rendered safe for use as a vaccine by the disruption of genes encoding reverse transcriptase, integrase, and Vif. The DNA molecule is further rendered safe by at least a partial deletion of the 3? LTR.Type: GrantFiled: July 18, 2011Date of Patent: July 22, 2014Assignee: University of Kansas Medical CenterInventor: Zhenqian Liu
-
Patent number: 8778351Abstract: The present invention relates to compositions that contain a chimeric papillomavirus virus-like particle (VLP) in combination with a DNA molecule encoding a protein or polypeptide epitope. The chimeric papillomavirus VLP is assembled from an L1 protein or polypeptide and a chimeric protein or polypeptide containing at least a portion of the L2 protein and a protein or polypeptide including an immunogenic epitope. The composition is useful for inducing an enhanced immune response against a pathogen or a tumor.Type: GrantFiled: August 30, 2007Date of Patent: July 15, 2014Assignee: University of RochesterInventors: Robert C. Rose, Christine Malboeuf, Young-Eun Ellen Lee
-
Publication number: 20140193458Abstract: A vaccination method is provided. The method comprises administering to a mammal a histone deacytelase inhibitor in conjunction with a vaccine that expresses an antigen to which the mammal has a pre-existing immunity.Type: ApplicationFiled: March 9, 2012Publication date: July 10, 2014Inventors: Byram Bridle, Brian Lichty, Yonghong Wan, Jean-Simon Diallo, Chantal Lemay, John Bell
-
Publication number: 20140186384Abstract: Improved anti-HIV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus sequences for HIV Subtype A Envelope protein, those having consensus sequences for HIV Subtype B Envelope protein, those having consensus sequences for HIV Subtype C Envelope protein, those having consensus sequences for HIV Subtype D Envelope protein, those having consensus sequences for HIV Subtype B consensus Nef-Rev protein, and those having consensus sequences form HIV Gag protein subtypes A, B, C and D. Improved anti-HPV immunogens and nucleic acid molecules that encode them; improved anti-HCV immunogens and nucleic acid molecules that encode them; improved hTERT immunogens and nucleic acid molecules that encode them; and improved anti-Influenza immunogens and nucleic acid molecules that encode them are disclosed as well methods of inducing an immune response in an individual against HIV, HPV, HCV, hTERT and Influenza are disclosed.Type: ApplicationFiled: December 23, 2013Publication date: July 3, 2014Applicant: The Trustees of the University of PennsylvaniaInventors: David B. Weiner, Jian Yan
-
Patent number: 8765140Abstract: The present invention is directed to a DNA vaccine for immunization against HIV. The invention comprises a DNA molecule that has a sequence encoding a plurality of viral proteins capable of stimulating an immune response against HIV. The DNA molecule is rendered safe for use as a vaccine by the disruption of genes encoding reverse transcriptase, integrase, and Vif. The DNA molecule is further rendered safe by at least a partial deletion of the 3? LTR.Type: GrantFiled: July 18, 2011Date of Patent: July 1, 2014Assignee: University of Kansas Medical CenterInventor: Zhenqian Liu
-
Publication number: 20140178426Abstract: The present invention provides for novel compositions and methods for delivering genes of interest to stem cells using vectors that contain differentiation-specific transcriptional regulatory elements. For example, stem cells in the internal epithelia could be transfected with a vaccine construct, which has an epithelial cell differentiation-specific promoter driving the expression of viral envelope proteins. When the promoter used is specific for terminally differentiated epithelial cells, then the viral envelope proteins will be expressed only in the upper part of the epithelia and therefore, stimulate the immune response. The infected epithelial stem cells in the basal layer will continue to produce new antigen-expressing cells, without being eliminated by the immune response. This invention will be useful in the development of vaccines against viral agents that target the internal mucosa like HIV.Type: ApplicationFiled: October 24, 2013Publication date: June 26, 2014Applicant: Texas Biomedical Research InstituteInventors: Marie-Claire Gauduin, Philippe Blancou
-
Patent number: 8748088Abstract: Provided herein are methods for detecting the presence of replication-competent HIV-1 virus in a subject who is being treated with an intensified highly active anti-retroviral therapy (HAART) regimen. These methods comprise selecting a subject who is being treated with an intensified HAART regimen including an integration inhibitor; obtaining a sample, e.g., a blood sample, from a subject; specifically amplifying a segment spanning two-long terminal repeat (2-LTR) junction of 2-LTR circles using PCR to determine the level of 2-LTR circles in the sample; and determining the presence of replication competent virus based on the level of 2-LTR circles in the sample. These methods can also be used to monitor an intensified HAART regimen by obtaining samples from the same subject at different time points during the HAART treatment, and comparing levels of the 2-LTR circles in those samples.Type: GrantFiled: January 29, 2010Date of Patent: June 10, 2014Assignee: University of MassachusettsInventor: Mario Stevenson
-
Patent number: 8747862Abstract: The claimed invention is directed toward an HIV-2 isolate designated NWK08F, including variants, and isolated proteins and nucleotides obtained from said isolates.Type: GrantFiled: November 13, 2009Date of Patent: June 10, 2014Assignee: Tulane University Health Sciences CenterInventors: Stephen M. Smith, Preston A. Marx
-
Patent number: 8741310Abstract: Isolated, antigenic polypeptides including a prehairpin intermediate conformation of gp41 and vectors encoding such polypeptides are provided. Antibodies that bind to a prehairpin intermediate conformation of gp41 and methods of making antibodies a that bind to prehairpin intermediate conformation of gp41 are also provided. Vaccines against a prehairpin intermediate conformation of gp41, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided. Methods of screening compounds that bind to an isolated, prehairpin intermediate conformation of gp41 are further provided.Type: GrantFiled: August 27, 2010Date of Patent: June 3, 2014Assignees: Children's Medical Center Corporation, President and Fellows of Harvard College, Howard Hughes Medical InstituteInventors: Bing Chen, Gary H. Frey, Stephen C. Harrison
-
Patent number: 8741308Abstract: The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into the new insertion site as medicine or vaccine.Type: GrantFiled: May 2, 2013Date of Patent: June 3, 2014Assignee: Bavarian Nordic A/SInventors: Paul Howley, Sonja Leyrer
-
Patent number: 8728723Abstract: The invention relates to a method for detecting, in vitro, an infection with a microorganism, such as the hepatitis C virus, in a biological sample, by simultaneously detecting an antigen of this microorganism and the antibodies against this same antigen, and also to the reagents and kits implementing this method.Type: GrantFiled: March 30, 2012Date of Patent: May 20, 2014Assignee: Bio-Rad InnovationsInventors: François Rieunier, Muriel Feyssaguet, Stéphanie Henriot, Nadine Lambert
-
Patent number: 8728485Abstract: The present invention provides artificial fusion proteins (AFPs) designed to elicit an anti-HIV immune response, as well as nucleic acid molecules and expression vectors encoding those proteins. The AFPs of the invention may comprise domains from various HIV proteins, such as Gag, Pol, Vif, and Env proteins, which are partial sequences. HIVCON is an AFP in which the HIV domains are from several HIV Glade consensus sequences and which optionally contains additional domains which may be useful, for example, in monitoring expression levels or laboratory animal immune responses. Other aspects of the invention may include compositions and methods for inducing an anti-HIV immune response in a subject, preferably with a DNA prime-MVA boost strategy, and to induce a cell-mediated immune response.Type: GrantFiled: March 17, 2010Date of Patent: May 20, 2014Assignee: Medical Research CouncilInventors: Tomas Hanke, Andrew James McMichael
-
Patent number: 8729234Abstract: The invention relates to a method for detecting, in vitro, an infection with a microorganism, such as the hepatitis C virus, in a biological sample, by simultaneously detecting an antigen of this microorganism and the antibodies against this same antigen, and also to the reagents and kits implementing this method.Type: GrantFiled: March 30, 2012Date of Patent: May 20, 2014Assignee: Bio-Rad InnovationsInventors: François Rieunier, Muriel Feyssaguet, Stéphanie Henriot, Nadine Lambert
-
Patent number: 8715684Abstract: A novel peptides are complexed with HIV-I envelope protein gp120, and causes the protein to assume a CD4i conformation but without occluding the CD4 binding-site of gp120. This peptide-gp120 complex is immunogenic and, upon immunization of subjects, induces broadly-neutralizing antibodies directed to the CD4 binding site of gp120. The peptide preferably consists of a sequence of 8-20 amino acid residues which comprises (a) a core sequence Arg-Xaa1-Asp-Leu-Pro-Xaa2-Trp-Ala (SEQ ID NO: 1) in which Xaa1 and Xaa2 is any amino acid, or (b) certain substitution variants of SEQ ID NO:1.Type: GrantFiled: August 28, 2008Date of Patent: May 6, 2014Assignee: Ramot at Tel Aviv University Ltd.Inventors: Jonathan M. Gershoni, Gal Dela
-
Patent number: 8715686Abstract: Isolated immunogens including a HIV-1 gp120 polypeptide or immunogenic fragment thereof stabilized in a CD4 bound confirmation by crosslinked cysteines, and methods of their use are disclosed. The immunogens are useful, for example, for generating an immune response to HIV-1 gp120 in a subject.Type: GrantFiled: August 14, 2012Date of Patent: May 6, 2014Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Dana-Faber Cancer Institute, Inc.Inventors: Peter Kwong, John Mascola, Gary Nabel, Richard Wyatt, Barna Dey, Ling Xu, Tongqing Zhou, Joseph Sodroski, Wen Yuan, Shi-Hua Xiang
-
Publication number: 20140112951Abstract: Disclosed and claimed is a method of non-invasive immunization in an animal and/or a method of inducing a systemic immune response or systemic therapeutic response to a gene product. The skin of the animal is contacted with a non-replicative vector chosen from the group of bacterium, virus, and fungus, wherein the vector comprises and expresses a nucleic acid molecule encoding the gene product, in an amount effective to induce the response.Type: ApplicationFiled: August 7, 2013Publication date: April 24, 2014Applicant: UAB RESEARCH FOUNDATIONInventors: De-Chu C. Tang, Zhongkai Shi, Kent Rigby van Kampen
-
Patent number: 8703142Abstract: Embodiments of the invention disclosed herein relate to methods and compositions for bypassing the involvement of CD4+ cells when generating antibody and MHC class I-restricted immune responses, controlling the nature and magnitude of the response, and promoting effective immunologic intervention in viral pathogenesis. More specifically, embodiments relate to immunogenic compositions for vaccination particularly therapeutic vaccination, against HIV and other microbial pathogens that impact functioning of the immune system, their nature, and the order, timing, and route of administration by which they are effectively used.Type: GrantFiled: December 29, 2005Date of Patent: April 22, 2014Assignee: Mannkind CorporationInventors: David C. Diamond, Adrian Ion Bot
-
Patent number: 8697084Abstract: Improved anti-HIV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus sequences for HIV Subtype A Envelope protein, those having consensus sequences for HIV Subtype B Envelope protein, those having consensus sequences for HIV Subtype C Envelope protein, those having consensus sequences for HIV Subtype D Envelope protein, those having consensus sequences for HIV Subtype B consensus Nef-Rev protein, and those having consensus sequences form HIV Gag protein subtypes A, B, C and D. Improved anti-HPV immunogens and nucleic acid molecules that encode them; improved anti-HCV immunogens and nucleic acid molecules that encode them; improved hTERT immunogens and nucleic acid molecules that encode them; and improved anti-Influenza immunogens and nucleic acid molecules that encode them are disclosed as well methods of inducing an immune response in an individual against HIV, HPV, HCV, hTERT and Influenza are disclosed.Type: GrantFiled: April 27, 2012Date of Patent: April 15, 2014Assignee: The Trustees of the University of PennsylvaniaInventors: David B Weiner, Jian Yan, Dominick Laddy
-
Publication number: 20140093556Abstract: The disclosure relates to immunological compositions for vaccinating human beings against infection by the Human Immunodeficiency Virus (HIV).Type: ApplicationFiled: January 26, 2012Publication date: April 3, 2014Applicants: SANOFI PASTEUR SA, POLYMUNE SCIENTIFIC IMMUNOBIOLOGISCHE FORSCHUNG GMBH, UNIVERSIDAD DE GRANADA, PX' THERAPEUTICSInventors: Francisco Conejero-Lara, Irene Luque, Pedro Luis Mateo, Andreas Wagner, Raphaelle Claude, Marie-Gaelle Roger, Nicolas Mouz, Christophe Martin
-
Publication number: 20140079735Abstract: Peptide vaccine that is a mixture of different peptide species, where each species has a number of fixed amino acid residues and a number of randomized residues. The fixed resides are the same amino acid residues at the corresponding positions in each species of the mixture while the randomized residues are randomly any available candidate amino acids chosen by design. The degree of randomization may be also been chosen according to the design under a particular situation. This type of peptide vaccines have shown to be able to induce highly specific antibodies against epitopes that are otherwise difficult to induce antibodies in vitro, for example the GPG triplet in the V3 of HIV-1 gp120.Type: ApplicationFiled: September 17, 2012Publication date: March 20, 2014Inventors: Zhiwei (Allen) Wu, Xilin Wu
-
Patent number: 8673612Abstract: The present invention relates to compositions and methods for producing an immune response or reaction, as well as to vaccines, kits, processes, cells and uses thereof. This invention more particularly relates to compositions and methods of using a synthetic viral particle to produce, modify or regulate an immune response in a subject. In a more preferred embodiment, the invention is based, generally, on compositions using synthetic viral particles as an adjuvant and/or vehicle to raise an immune response against selected antigen(s) or epitopes, in particular a cellular and/or a humoral immune response.Type: GrantFiled: October 25, 2001Date of Patent: March 18, 2014Assignee: L'Universite Pierre et Marie CurieInventors: David Klatzmann, Jean-Loup Salzmann, Bertrand Bellier, Charlotte Frisen, François-Loïc Cosset
-
Patent number: 8673311Abstract: The present invention relates to a method of coating a spore with one or more therapeutic agents. The present invention also relates to a coated spore obtained by the method of the present invention and the use of the coated spore as a vaccine.Type: GrantFiled: September 21, 2010Date of Patent: March 18, 2014Assignee: Royal Holloway and Bedford New CollegeInventors: Simon Michael Cutting, Hong Anh Huynh